Cargando…

Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis

Sodium-glucose cotransporter-2 (SGLT2) inhibitors represent newly developed oral antidiabetic drugs that are practiced for type 2 diabetes mellitus management and may decrease the risk of the first hospitalization in heart failure. The activity of SGLT2 inhibitors is not related to glucose, and the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Ru-ping, Xu, Yu-li, Su, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026320/ https://www.ncbi.nlm.nih.gov/pubmed/33859839 http://dx.doi.org/10.1155/2021/6657380

Ejemplares similares

Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis
por: Ali, Ahmed E., et al.
Publicado: (2023)

Efficacy and safety of dapagliflozin in the treatment of chronic heart failure: A protocol for systematic review and meta-analysis
por: Dong, Xueyan, et al.
Publicado: (2021)

Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review
por: Wu, Meiyu, et al.
Publicado: (2022)

Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
por: Mohammadnezhad, Ghader, et al.
Publicado: (2022)

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
por: Gupta, Manasvi, et al.
Publicado: (2021)

Effect of Dapagliflozin on Exercise Capacity and Cardiovascular Risk in Patients with Heart Failure
por: Nazer, Rakan, et al.
Publicado: (2022)

Dapagliflozin initiation in chronic heart failure patients improves central sleep apnoea
por: Jaffuel, Dany, et al.
Publicado: (2023)

Sarcopenia in heart failure: a systematic review and meta‐analysis
por: Zhang, Yan, et al.
Publicado: (2021)

Current Status of Dapagliflozin in Congestive Heart Failure
por: Palandurkar, Gopal, et al.
Publicado: (2022)

Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
por: Williams, David M., et al.
Publicado: (2020)

Multicomponent integrated care for patients with chronic heart failure: systematic review and meta‐analysis
por: Yang, Ya‐Feng, et al.
Publicado: (2022)

Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
por: Blair, Hannah A.
Publicado: (2021)

Readmission Risk Prediction Model for Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis
por: Liu, Jing, et al.
Publicado: (2022)

Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics
por: Yeoh, Su Ern, et al.
Publicado: (2023)

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021)

Telerehabilitation Approaches for People with Chronic Heart Failure: A Systematic Review and Meta-Analysis
por: Isernia, Sara, et al.
Publicado: (2022)

Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis
por: Shi, Zepeng, et al.
Publicado: (2022)

Effect of advanced nursing care on psychological condition in patients with chronic heart failure: A protocol of systematic review and meta-analysis
por: Lin, Yang, et al.
Publicado: (2020)

Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER
por: Butt, Jawad H, et al.
Publicado: (2023)

The Effects of Dapagliflozin in Patients With Heart Failure Complicated With Type 2 Diabetes: A Meta-Analysis of Placebo-Controlled Randomized Trials
por: Zhai, Miaobo, et al.
Publicado: (2021)

Mortality and Readmission Rates After Heart Failure: A Systematic Review and Meta-Analysis
por: Lan, Tian, et al.
Publicado: (2021)

The effect of Dapagliflozin on renal functions in hospitalized patients with Acute Heart Failure
por: Gilani, Syedah Fauzia Fatima, et al.
Publicado: (2023)

Effect of grelin on TRX expression in chronic heart failure tissue: A protocol of systematic review and meta-analysis
por: Chen, Zhe, et al.
Publicado: (2020)

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF
por: Dewan, Pooja, et al.
Publicado: (2021)

Corrigendum to: Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER
Publicado: (2023)

Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin
por: Escobar, Carlos, et al.
Publicado: (2023)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
por: Wang, Dong-Dong, et al.
Publicado: (2022)

Ligustrazine Injection for Chronic Pulmonary Heart Disease: A Systematic Review and Meta-Analysis
por: Jian-sheng, Li, et al.
Publicado: (2012)

Chinese Herbal Medicines and Conventional Chronic Heart Failure Treatment for the Management of Chronic Heart Failure Complicated with Depression: A Systematic Review and Meta-Analysis
por: Yang, Peidan, et al.
Publicado: (2020)

Rationale and Design of the ADIDAS Study: Association Between Dapagliflozin-Induced Improvement and Anemia in Heart Failure Patients
por: Zeng, Jianping, et al.
Publicado: (2021)

Effects of Different Telemonitoring Strategies on Chronic Heart Failure Care: Systematic Review and Subgroup Meta-Analysis
por: Ding, Hang, et al.
Publicado: (2020)

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
por: Docherty, Kieran F, et al.
Publicado: (2020)

Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
por: Isaza, Nicolas, et al.
Publicado: (2021)

Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
por: Håkansson, Erik, et al.
Publicado: (2021)

Dapagliflozin for heart failure according to body mass index: the DELIVER trial( )
por: Adamson, Carly, et al.
Publicado: (2022)

Cost‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines
por: Mendoza, Victor L., et al.
Publicado: (2021)

Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
por: Vardeny, Orly, et al.
Publicado: (2022)

Effect of Baduanjin exercise on patients with chronic heart failure: protocol for a systematic review and meta-analysis
por: Li, Jieying, et al.
Publicado: (2019)

Exercise-based rehabilitation for heart failure: systematic review and meta-analysis
por: Sagar, Viral A, et al.
Publicado: (2015)

Effect of Air Pollution on Heart Failure: Systematic Review and Meta-Analysis
por: Jia, Yanhui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9te1tg7q3s8vq8vhlekmog9ei2